{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031390","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.972852+00:00","generated_at":"2026-06-08T05:15:26.785022+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin reports Q3 2023 cash of $24.6M; advances Annamycin in AML and STS","bullets":["Cash and equivalents $24.6M as of Sep 30, 2023; runway estimated into Q3 2024.","R&D expense $3.3M, down 45% YoY from $6.0M; G&A $2.6M, down 16% from $3.1M.","Dosed first subjects in Phase 2 trial of Annamycin + Cytarabine for AML (MB106).","Completed enrollment in U.S. Phase 1b/2 trial of Annamycin for STS lung metastases (MB107).","Independent assessment confirmed absence of cardiotoxicity in Annamycin-treated subjects."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031390","json":"https://secwatch.observer/filing/0001437749-23-031390.json","markdown":"https://secwatch.observer/filing/0001437749-23-031390.md","text":"https://secwatch.observer/filing/0001437749-23-031390.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/0001437749-23-031390-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/mbrx20231109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:15:26.785022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd17de6aca674cf3d81caa288551f036e5745887","claim":"Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/0001437749-23-031390-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}